^
    Back
    Association details:
    Biomarker:EGFR mutation + BRAF V600E
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Anticancer Drugs
    Title:

    Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations

    Published date:
    08/14/2023
    Excerpt:
    In conclusion, the combination therapy of osimertinib, dabrafenib, and trametinib shows promise as a targeted therapeutic option for patients with advanced NSCLC harboring both BRAF V600E and EGFR mutations.
    DOI:
    10.1097/CAD.0000000000001537
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    NPJ Precis Oncol
    Title:

    Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

    Published date:
    02/12/2021
    Excerpt:
    We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. Moreover, the patient experienced remarkable clinical improvement and good tolerance to combination therapy. 
    DOI:
    10.1038/s41698-021-00149-4